CA3002767C - Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer - Google Patents

Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer Download PDF

Info

Publication number
CA3002767C
CA3002767C CA3002767A CA3002767A CA3002767C CA 3002767 C CA3002767 C CA 3002767C CA 3002767 A CA3002767 A CA 3002767A CA 3002767 A CA3002767 A CA 3002767A CA 3002767 C CA3002767 C CA 3002767C
Authority
CA
Canada
Prior art keywords
cancer
cbd
cheh
aebs
cannabidiol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3002767A
Other languages
English (en)
French (fr)
Other versions
CA3002767A1 (en
Inventor
Zvi VOGEL
Lakshmi Narasaiah UPPALAPATI
Adela Juknat GERALNIK
Ilana Nathan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akos Biosciences Inc
Original Assignee
Jay Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jay Pharma Inc filed Critical Jay Pharma Inc
Priority to CA3187317A priority Critical patent/CA3187317A1/en
Publication of CA3002767A1 publication Critical patent/CA3002767A1/en
Application granted granted Critical
Publication of CA3002767C publication Critical patent/CA3002767C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3002767A 2015-10-27 2016-10-27 Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer Active CA3002767C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3187317A CA3187317A1 (en) 2015-10-27 2016-10-27 Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562246780P 2015-10-27 2015-10-27
US62/246,780 2015-10-27
PCT/IL2016/051166 WO2017072773A1 (en) 2015-10-27 2016-10-27 Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3187317A Division CA3187317A1 (en) 2015-10-27 2016-10-27 Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer

Publications (2)

Publication Number Publication Date
CA3002767A1 CA3002767A1 (en) 2017-05-04
CA3002767C true CA3002767C (en) 2023-03-14

Family

ID=57406292

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3002767A Active CA3002767C (en) 2015-10-27 2016-10-27 Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
CA3187317A Pending CA3187317A1 (en) 2015-10-27 2016-10-27 Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3187317A Pending CA3187317A1 (en) 2015-10-27 2016-10-27 Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer

Country Status (10)

Country Link
US (1) US11090275B2 (enExample)
EP (1) EP3368024B1 (enExample)
JP (1) JP7078538B2 (enExample)
KR (1) KR20180102053A (enExample)
CN (1) CN109310648B (enExample)
AU (1) AU2016347662B2 (enExample)
BR (1) BR112018008601A2 (enExample)
CA (2) CA3002767C (enExample)
IL (1) IL258854B2 (enExample)
WO (1) WO2017072773A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020161083A1 (en) * 2019-02-04 2020-08-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating blood-brain barrier
EP3993780A4 (en) * 2019-07-02 2023-07-26 Portland Technology Holdings LLC HEMP EXTRACT FOR THE TREATMENT OF PAIN, CANCER AND EPILEPSY IN ANIMALS
CA3109520C (en) * 2019-07-21 2021-09-07 Scf Pharma Inc. Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof
EP4132486A4 (en) * 2020-04-09 2024-04-03 Laviolette, Steven Robert Combination of cannabidiol and a ppar agonist
CN111773390B (zh) * 2020-07-01 2021-08-20 南京大学 一种药物在制备治疗脑转移瘤及其相关疾病的药品中的应用
CN113368085A (zh) * 2021-06-05 2021-09-10 昆明医科大学第一附属医院 大麻二酚在调节肿瘤微生态治疗乳腺癌药物研制中的应用
CN113384563A (zh) * 2021-06-16 2021-09-14 冯敏 大麻二酚在制备治疗非霍奇金淋巴瘤的药物中的应用
KR20240116463A (ko) 2021-10-26 2024-07-29 더 유니버시티 오브 뉴캐슬 대마 추출물을 이용한 자궁내막증 및 기타 비암성 부인과 장애의 치료 방법
WO2023076931A2 (en) 2021-10-26 2023-05-04 Ecofibre Limited Systems and methods for producing hemp extracts and compositions
IL312273A (en) 2021-10-26 2024-06-01 Ecofibre Usa Inc Methods for treating endometrial cancer using hemp extract
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
WO2024003373A1 (en) * 2022-06-30 2024-01-04 Univerza V Mariboru Cannabinoid compositions against cancer, their identification and personalization of cannabis-based cancer therapy
US20240009211A1 (en) * 2022-07-05 2024-01-11 Neocannbio Co., Ltd. Pharmaceutical composition for treatment of lung cancer comprising cannabidiol and anticancer agent as active ingredients, and use thereof
KR20240036953A (ko) * 2022-09-14 2024-03-21 주식회사 네오켄바이오 칸나비디올 및 항암제를 유효성분으로 포함하는 간암 치료용 약학 조성물 및 이의 용도
WO2024091987A1 (en) 2022-10-26 2024-05-02 Ecofibre USA Inc. Methods of treating estrogen sensitive diseases with cannabis extract
WO2024091989A1 (en) 2022-10-26 2024-05-02 Ecofibre USA Inc. Stabilized compositions comprising cannabidiol
WO2024097631A2 (en) * 2022-11-02 2024-05-10 Morehouse School Of Medicine Methods of treating pain and drepression

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
AU664978B2 (en) * 1990-12-17 1995-12-14 University Of Manitoba Improved treatment method for cancer
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6380253B1 (en) * 2000-01-05 2002-04-30 Efa Sciences Llc Method of stabilizing and potentiating the action of anti-angiogenic substances
US20020040011A1 (en) * 2000-06-01 2002-04-04 Brown Dennis M. Naphthoquinone compositions and uses thereof
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
US9084771B2 (en) * 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2475183B (en) 2008-06-04 2011-11-23 Gw Pharma Ltd Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators
FR2947340B1 (fr) * 2009-06-25 2011-08-12 Affichem Detection de l'etat oncogene de cellules humaines ou de mammiferes par presence d'un marqueur et evaluation de l'activite d'un medicament par dosage dudit marqueur
GB201117956D0 (en) 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
GB2515312A (en) 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
GB2527590A (en) * 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer

Also Published As

Publication number Publication date
AU2016347662A1 (en) 2018-05-10
IL258854B2 (en) 2025-06-01
KR20180102053A (ko) 2018-09-14
JP7078538B2 (ja) 2022-05-31
EP3368024B1 (en) 2023-09-20
IL258854B1 (en) 2025-02-01
CN109310648B (zh) 2022-06-03
CA3187317A1 (en) 2017-05-04
AU2016347662B2 (en) 2021-12-02
EP3368024A1 (en) 2018-09-05
US11090275B2 (en) 2021-08-17
CN109310648A (zh) 2019-02-05
WO2017072773A1 (en) 2017-05-04
BR112018008601A2 (pt) 2018-10-30
US20180311182A1 (en) 2018-11-01
CA3002767A1 (en) 2017-05-04
IL258854A (en) 2018-06-28
JP2018536706A (ja) 2018-12-13

Similar Documents

Publication Publication Date Title
CA3002767C (en) Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
US20220054429A1 (en) Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
US10098867B2 (en) Use of phytocannabinoids in the treatment of ovarian carcinoma
Davis et al. Topical Coenzyme Q10 demonstrates mitochondrial-mediated neuroprotection in a rodent model of ocular hypertension
Pawlik et al. Sensitization of estrogen receptor-positive breast cancer cell lines to 4-hydroxytamoxifen by isothiocyanates present in cruciferous plants
Si et al. Silibinin-induced apoptosis of breast cancer cells involves mitochondrial impairment
US20120045532A1 (en) Anticancer Methods Employing Extracts of Gleditsia sinensis Lam
JP5620443B2 (ja) 抗ｅｇｆｒ療法に二次的な皮疹の予防および処置のためのビタミンｋ
Si et al. Silibinin-induced mitochondria fission leads to mitophagy, which attenuates silibinin-induced apoptosis in MCF-7 and MDA-MB-231 cells
US9138477B2 (en) Uses for 4,17β-dihydroxyandrost-4-ene-3-one
CN102083430A (zh) 大麻类化合物组合物的抗肿瘤作用
MXPA01005641A (es) Metodo y composicion para el tratamiento de cancer usando aceites vegetales esenciales naturales.
Liu et al. Anti-neoplastic activity of low-dose endothelial-monocyte activating polypeptide-II results from defective autophagy and G2/M arrest mediated by PI3K/Akt/FoxO1 axis in human glioblastoma stem cells
Wang et al. Melatonin protects against Epirubicin-induced ovarian damage
Jumnongprakhon et al. Protective effect of melatonin on methamphetamine-induced apoptosis in glioma cell line
US20090233881A1 (en) Compounds having anti-cancer properties
Endharti et al. Dendrophthoe pentandra leaves extract promotes apoptotic effects of doxorubicin in human breast cancer cell via modulation of intracellular calcium and survivin
Lin et al. PF-429242 exhibits anticancer activity in hepatocellular carcinoma cells via FOXO1-dependent autophagic cell death and IGFBP1-dependent anti-survival signaling
Da Fonseca et al. Anaplastic oligodendroglioma responding favorably to intranasal delivery of perillyl alcohol: a case report and literature review
Huang et al. Quinolinic acid induces cell apoptosis in PC12 cells through HIF-1-dependent RTP801 activation
Awounfack et al. Ethanol‐Extracted Cameroonian Propolis Counteracts Tamoxifen‐Induced Endometrial Hyperplasia by Modulating Apoptosis and Proliferation‐Regulating Proteins in the Ovaries of Intact Wistar Rats
Awounfack et al. Research Article Ethanol-Extracted Cameroonian Propolis Counteracts Tamoxifen-Induced Endometrial Hyperplasia by Modulating Apoptosis and Proliferation-Regulating Proteins in the Ovaries of Intact Wistar Rats
Haq et al. ROLE OF ASCORBIC ACID ON ALTERED LEVELS OF TESTOSTERONE DURING CHEMOTHERAPY
AU2006220247B2 (en) Compounds having anti-cancer properties
Ye Mechanisms of anticancer activities of (-)-gossypol-enriched cottonseed oil against human breast cancer cells

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191030

EEER Examination request

Effective date: 20191030

EEER Examination request

Effective date: 20191030

EEER Examination request

Effective date: 20191030